A photograph displaying the emblem of Swiss pharmaceutical big Roche in Basel.
SEBASTIEN BOZON | AFP | Getty Photographs
Roche’s first-half web revenue rose 2% to eight.22 billion Swiss francs ($8.96 billion) and gross sales elevated by 8% at fixed trade charges to a better-than anticipated 30.71 billion francs because the Swiss drugmaker benefited from demand for Covid-19 assessments.
It maintained its full-year forecast for gross sales to develop at a low- to mid-single-digit fee at fixed trade charges, with core earnings per share rising about the identical as gross sales.
“Roche expects to extend its dividend in Swiss francs additional,” it added. Diagnostics division gross sales grew 51% within the first half attributable to excessive demand for Covid-19 assessments and robust momentum in routine testing, Roche mentioned, serving to to compensate for a 3% decline in prescribed drugs gross sales, though drug gross sales rose within the second quarter after a weak begin to the 12 months.
“We now have achieved good ends in the primary half, primarily because of the demand for our new medicines and Covid-19 assessments. The Pharma Division started to develop once more within the second quarter. The bottom diagnostics enterprise reveals sturdy momentum. As anticipated, demand for Covid-19 assessments peaked within the second quarter,” Chief Government Severin Schwan mentioned.